drug_type
RELEVANT_DRUG
intervention_type
Cellular immunotherapy (CAR T-cell)
drug_description
Autologous anti-CD19 CAR T-cell therapy; patient T cells are engineered to express a CD19-directed chimeric antigen receptor, activating T-cell cytotoxicity to eliminate CD19+ malignant and normal B cells (often causing B-cell aplasia).
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
brexucabtagene autoleucel
drug_category
CAR T
drug_class
Cellular Therapy
drug_delivery_route
Intravenous
drug_mechanism_of_action
Autologous T cells are engineered ex vivo to express a CD19-directed chimeric antigen receptor; upon binding CD19 on malignant and normal B cells, CAR signaling activates T-cell cytotoxicity and cytokine release, resulting in targeted lysis and depletion of CD19+ cells (often causing B-cell aplasia).
drug_name
KTE-X19 (brexucabtagene autoleucel)
nct_id_drug_ref
NCT06253663